Story perspectives

Astellas Innovates Immuno-Oncology Treatments for Remote Patients

10/8/2025

39 8

Summary

Story summary

Astellas aims to deliver immuno-oncology therapies for patients unresponsive to treatments, guided by Focus, Enrich, and Expand.
The company has a track record in oncology, ophthalmology, urology, immunology, and women’s health.
Subcutaneous immune checkpoint inhibitors reduce wait times and streamline treatment.
Home-based administration is growing for remote patients, with four focus areas: Blindness and Regeneration; Genetic Regulation; Immuno-Oncology; Targeted Protein Degradation.

1 of 1

Story summary

Astellas aims to deliver immuno-oncology therapies for patients unresponsive to treatments, guided by Focus, Enrich, and Expand.
The company has a track record in oncology, ophthalmology, urology, immunology, and women’s health.
Subcutaneous immune checkpoint inhibitors reduce wait times and streamline treatment.
Home-based administration is growing for remote patients, with four focus areas: Blindness and Regeneration; Genetic Regulation; Immuno-Oncology; Targeted Protein Degradation.